Form 8-K - Current report:
SEC Accession No. 0001558370-22-014484
Filing Date
2022-09-20
Accepted
2022-09-20 08:05:43
Documents
15
Period of Report
2022-09-20
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K aytu-20220920x8k.htm   iXBRL 8-K 35215
2 EX-99.1 aytu-20220920xex99d1.htm EX-99.1 12521
3 GRAPHIC aytu-20220920xex99d1001.jpg GRAPHIC 6634
  Complete submission text file 0001558370-22-014484.txt   266398

Data Files

Seq Description Document Type Size
4 EX-101.SCH aytu-20220920.xsd EX-101.SCH 3249
5 EX-101.LAB aytu-20220920_lab.xml EX-101.LAB 634
6 EX-101.PRE aytu-20220920_pre.xml EX-101.PRE 10406
9 EXTRACTED XBRL INSTANCE DOCUMENT aytu-20220920x8k_htm.xml XML 4866
Mailing Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112
Business Address 373 INVERNESS PARKWAY SUITE 206 ENGLEWOOD CO 80112 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

EIN.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 221252100
SIC: 2834 Pharmaceutical Preparations